Vertex Pharmaceuticals Reports 12% Revenue Growth to $3.33 Billion in Q2 2026

Vertex Pharmaceuticals Incorporated reported strong financial results for the second quarter of 2026, with total revenues reaching $3.33 billion, a 12% increase from $2.96 billion in the same period last year. The growth was primarily driven by robust sales of its cystic fibrosis (CF) therapies, particularly the ALYFTREK product, which saw a significant rise in revenue. Net income for the quarter was $1.10 billion, or $4.34 per share, compared to $1.03 billion, or $4.02 per share, in the prior year, reflecting a 6.5% increase in profitability.

In terms of operational metrics, Vertex's product revenues for the first half of 2026 totaled $6.32 billion, up from $5.73 billion in the first half of 2025. The company reported a notable increase in sales of CASGEVY, which generated $76.4 million in the second quarter, marking a 151% increase year-over-year. Additionally, JOURNAVX revenues surged to $49.6 million, a 313% increase compared to the same quarter last year. The company also expanded its geographic footprint, securing reimbursement for ALYFTREK in four additional countries, bringing the total to 25.

Vertex's total costs and expenses for the second quarter were $2.09 billion, a 15% increase from $1.81 billion in the prior year. This rise was attributed to higher selling, general, and administrative expenses, which increased by 37% to $582.2 million, as the company invested in commercializing new products. Research and development expenses remained stable at $993.8 million, reflecting ongoing investments in its pipeline, which includes treatments for various serious diseases beyond CF.

Looking ahead, Vertex has announced plans to acquire Crinetics Pharmaceuticals for approximately $10 billion, a move expected to enhance its portfolio in the endocrine disease market. The acquisition is anticipated to close in the third quarter of 2026, funded through a combination of cash and a new $4.5 billion term loan. Vertex's cash, cash equivalents, and marketable securities increased to $13.64 billion as of June 30, 2026, up from $12.32 billion at the end of 2025, providing a solid financial foundation for future growth and strategic initiatives. The company remains optimistic about its ability to continue expanding its product offerings and market presence.